Inventiva reported its financial information for the first quarter of 2025, with cash and cash equivalents amounting to €67.9 million as of March 31, 2025, a decrease of €28.7 million from December 31, 2024. This decrease is primarily attributed to net cash used in operating activities for the lanifibranor development program.
The company did not recognize any revenues for the first quarter of 2025, consistent with the first quarter of 2024. However, Inventiva's financial outlook significantly improved with the settlement of the second tranche of its structured financing on May 7, 2025, which provided €115.6 million in gross proceeds.
Considering these proceeds and an anticipated $10 million milestone payment from CTTQ, along with the ongoing pipeline prioritization plan, Inventiva estimates its cash and cash equivalents will be sufficient to fund operations until the end of the third quarter of 2026. This extended cash runway is critical for advancing lanifibranor through its pivotal development stages.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.